A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy.

Trial Profile

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Celecoxib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms REMAGUS-02
  • Most Recent Events

    • 06 Mar 2017 Results of long-term follow-up for disease-free survival and overall survival published in the European Journal of Cancer
    • 08 Dec 2012 Results for disease-free survival and overall survival in HER2 positive patients treated with or without trastuzumab presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2012 Results for overall survival and disease-free survival in HER2-negative patients treated with or without celecoxib presented at the 35th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top